Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
China (Chinese)
登录/注册 UserName
产品

Link Arrow
解决方案

Link Arrow
发现&学习

Link Arrow
资源&工具

Link Arrow
Support

Link Arrow
Search icon Search icon
Close Menu
      Alert Icon
      Purified NA/LE Mouse Anti-Human CD253
      Purified NA/LE Mouse Anti-Human CD253
      Flow Cytometric Analysis of TRAIL-induced Killing and RIK-2 Blocking using FITC Annexin V staining.  Jurkat T cells were left untreated (far left/first panel) or treated for 16 hours under the following conditions: Cells were incubated with 20 ng/ml of recombinant human TRAIL and 10 µg/ml anti-histidine antibody (second panel); or with 20 ng/ml of recombinant human TRAIL and 10 µg/ml anti-histidine antibody preincubated with RIK-2 antibody (third panel); or with 20 ng/ml of recombinant human TRAIL and 10 µg/ml anti-histidine antibody preincubated with mIgG1 antibody (negative control) (far right/fourth panel). Following treatments, cells were evaluated for Annexin-V staining. Cells induced to undergo apoptosis by treatment with recombinant human TRAIL gave a population of cells that was Annexin V-FITC positive (second panel, M2). Annexin V-FITC staining was blocked when cells were incubated with a mixture of recombinant human TRAIL and RIK-2 antibody (third panel, M2). Cells treated with the mixture of recombinant TRAIL and mIgG1 antibody could not block the killing (far right/fourth panel). A small number of Annexin-V positive cells in the untreated population represents a basal level of apoptosis (far left/first panel). The results indicate that clone RIK-2 can block cell mediated killing induced by recombinant human TRAIL as measured by Annexin V-FITC staining of Jurkat cells.
      Purified NA/LE Mouse Anti-Human CD253
      Flow Cytometric Analysis of TRAIL-induced Killing and RIK-2 Blocking using FITC Annexin V staining.  Jurkat T cells were left untreated (far left/first panel) or treated for 16 hours under the following conditions: Cells were incubated with 20 ng/ml of recombinant human TRAIL and 10 µg/ml anti-histidine antibody (second panel); or with 20 ng/ml of recombinant human TRAIL and 10 µg/ml anti-histidine antibody preincubated with RIK-2 antibody (third panel); or with 20 ng/ml of recombinant human TRAIL and 10 µg/ml anti-histidine antibody preincubated with mIgG1 antibody (negative control) (far right/fourth panel). Following treatments, cells were evaluated for Annexin-V staining. Cells induced to undergo apoptosis by treatment with recombinant human TRAIL gave a population of cells that was Annexin V-FITC positive (second panel, M2). Annexin V-FITC staining was blocked when cells were incubated with a mixture of recombinant human TRAIL and RIK-2 antibody (third panel, M2). Cells treated with the mixture of recombinant TRAIL and mIgG1 antibody could not block the killing (far right/fourth panel). A small number of Annexin-V positive cells in the untreated population represents a basal level of apoptosis (far left/first panel). The results indicate that clone RIK-2 can block cell mediated killing induced by recombinant human TRAIL as measured by Annexin V-FITC staining of Jurkat cells.
      商品详情
      Down Arrow Up Arrow


      BD Pharmingen™
      TNFSF10; TRAIL; APO-2L; TL2
      Human (QC Testing)
      Mouse IgG1
      Human TRAIL Transfected Cell Line
      Flow cytometry (Routinely Tested), Bioassay, Blocking (Tested During Development)
      1.0 mg/ml
      AB_393955
      No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
      RUO


      准备和存储

      Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      商品通知

      1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      2. An isotype control should be used at the same concentration as the antibody of interest.
      3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow
      550912 Rev. 6
      抗体详情
      Down Arrow Up Arrow
      RIK-2

      The RIK-2 monoclonal antibody specifically binds to CD253, also known as TRAIL (TNF-Related Apoptosis-Inducing Ligand) and Apo2 ligand (APO-2L). CD253 is a member of the Tumor Necrosis Factor Superfamily and is encoded by the TNFSF10 gene. CD253 is a type II membrane protein that may be expressed as a soluble as well as full-length, cell surface-associated protein. Both surface and soluble forms of TRAIL rapidly induce apoptosis in a wide range of tumor cell lines but not normal tissue. TRAIL is expressed by activated T cells, NK cells, dendritic cells, monocytes and a variety of non-lymphoid cells. TRAIL can bind to and exert apoptosis through DR4 (TRAIL-R1) and DR5 (TRAIL-R2) receptors. It can also bind to decoy receptors, including DcR1/TRID/TRAIL-R3 and DcR2/TRUNDD/TRAIL-R4, and possibly OPG/TNFRSF11B, which may serve to regulate TRAIL activity. TRAIL has been shown to be involved in T cell-mediated cytotoxicity, but its mechanism of action remains to be fully elucidated. The RIK-2 clone was selected based on its ability to block TRAIL-mediated cytotoxic activity.

      550912 Rev. 6
      格式详情
      Down Arrow Up Arrow
      NA/LE
      NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.
      NA/LE
      550912 Rev.6
      报价单和参考
      Down Arrow Up Arrow
      View product citations for antibody "550912" on CiteAb

      研发参考 (6)

      1. Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol. 1999; 162(5):2639-2647. (Immunogen: Blocking). 查看参考
      2. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol. 1997; 137(1):221-229. (Biology). 查看参考
      3. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol. 1996; 6(6):750-752. (Biology). 查看参考
      4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271(22):12687-12690. (Biology). 查看参考
      5. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997; 277(5327):818-821. (Biology). 查看参考
      6. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995; 3(6):673-682. (Biology). 查看参考
      查看所有文件 (6) 查看更少内容
      550912 Rev. 6

      Please refer to Support Documents for Quality Certificates

       

      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

       

      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.